## CLX: The Clorox Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 2.0% below STRENGTH zone (3.0-6.0%); PEG 3.19 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($96.79)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Cloroxâ€™s 5% Yield Looks Solid but One Metric Deserves Attention**
- Source: 24/7 Wall St. | 20251230T141940 | Somewhat-Bearish | Relevance: 100%
- Clorox's 5% dividend yield, while attractive, shows concerning trends in its free cash flow payout ratio and shareholder equity. Although the company improved its payout ratio to 79% in fiscal 2025 from 123% in fiscal 2024, its shareholder equity has significantly declined. Management expresses confidence in the balance sheet despite anticipated tariff headwinds, but the market's reaction and cash flow volatility suggest elevated risk for income investors.

**2. VIRGINIA RETIREMENT SYSTEMS ET Al Acquires 449,000 Shares of The Clorox Company $CLX**
- Source: MarketBeat | 20251231T115832 | Neutral | Relevance: 100%
- Virginia Retirement Systems increased its stake in The Clorox Company by buying an additional 449,000 shares, bringing its total to 450,800 shares valued at approximately $55.6 million. Other institutional investors like Invesco and Norges Bank also significantly increased their positions, leading to institutional investors owning about 78.53% of Clorox stock. Despite beating quarterly EPS estimates, Clorox reported an 18.9% year-over-year revenue decrease and has a "Reduce" consensus analyst rating.

**3. Boston Trust Walden Corp Sells 304,102 Shares of The Clorox Company $CLX**
- Source: MarketBeat | 20251231T094843 | Neutral | Relevance: 100%
- Boston Trust Walden Corp significantly reduced its stake in The Clorox Company ($CLX) by selling 304,102 shares in Q3, retaining only 3,048 shares. This comes as Clorox reported a Q3 EPS of $0.85, beating estimates, but revenue decreased by 18.9% year-over-year. Insider activity includes Director Pierre R. Breber acquiring 4,000 shares, increasing his ownership to 13,000 shares.

**4. Albion Financial Group UT Trims Stock Holdings in The Clorox Company $CLX**
- Source: MarketBeat | 20251231T084803 | Somewhat-Bearish | Relevance: 100%
- Albion Financial Group UT significantly reduced its stake in The Clorox Company ($CLX) by 99.1% in the third quarter, selling 34,585 shares and retaining only 304 shares. This divestment contrasts with major institutional investors like Vanguard, Invesco, and Norges Bank, which increased or initiated large positions in CLX. Analysts have a cautious outlook, with an average "Reduce" rating and several firms lowering price targets.

**5. My 3 Favorite Stocks to Buy Right Now**
- Source: The Globe and Mail | 20251231T183658 | Somewhat-Bullish | Relevance: 72%
- An investor details strategic tax-loss harvesting by selling Hormel and Clorox, with plans to repurchase them in early 2026, while concurrently adding to General Mills. The article highlights these three consumer staples companies as favorites due to their historically high dividend yields and reliable performance despite current industry headwinds. The author emphasizes a long-term investment approach to benefit from temporary market downturns in the consumer staples sector.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Citigroup | $109 | $120 | -9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 6 ($10.20M) |
| Sells | 11 ($0.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (-0.7%)
- Blackrock Inc.: 8.5% (-1.2%)
- State Street Corpora: 6.9% (+3.5%)
- Invesco Ltd.: 3.3% (+23.1%)
- Morgan Stanley: 2.6% (+18.3%)

### Key Risks

1. Valuation stretched: PEG 3.2x requires aggressive growth execution.
2. Long-term trend broken: trading 18.1% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_10 improving +5.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.19 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 44%, ROA 12%). Analyst sentiment negative (1 target cuts vs 0 raises). Insider buying signal ($10.2M), management confidence. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.3B |
| Beta | 0.57 |
| 52W Range | $96.66 - $164.22 |
| Short Interest | 6.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.19 |
| Forward P/E | 14.9 |
| Current P/E | 16.9 |
| YoY Growth | 12.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.4% to 2.0% (+5.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.0pp (needs >3.0% for momentum thesis). MRS_5 at 2.3% confirms short-term momentum alignment. Below SMA200 (0.82x), long-term trend not supportive. RSI neutral at 46. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.98% (CS: 96) | Neutral |
| RSI_14 | 45.6 | Neutral |
| MACD Histogram | 0.33 | Bullish |
| vs SMA20 | 0.998x | Below |
| vs SMA50 | 0.957x | Below |
| vs SMA200 | 0.819x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $100.83
- **Stop Loss:** $96.79 (4.0% risk)
- **Target:** $104.87 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 297
- **Position Value:** $29,946.51
- **Portfolio %:** 29.95%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-02-03 (Est: $1.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.78 | $0.85 | +9.2% |
| 2025Q2 | $2.21 | $2.87 | +29.8% |
| 2025Q1 | $1.56 | $1.45 | -6.9% |
| 2024Q4 | $1.40 | $1.55 | +10.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*